Towa Pharmaceutical Europe, S.L. – FDA 483, Sep 9, 2022
An FDA inspection of Towa Pharmaceutical Europe, S.L. in Martorelles, Barcelona, Spain, a drug manufacturer, revealed significant deficiencies across its quality systems. Observations included failures in thoroughly reviewing discrepancies related to IT system audit trails and sample set abortions, inadequate complaint handling procedures for adverse events, and insufficient cleaning validation studies. Additionally, the firm's annual product reviews were found to be deficient, not including all relevant batches.
ID · 2c556257-4901-4d7c-a4d1-2a060614bdc3
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.